These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 21985132)

  • 1. Eligibility, compliance and persistence of extended adjuvant endocrine therapy for breast cancer.
    Myrick ME; Schmid SM; Kilic N; Güth U
    Acta Oncol; 2012 Feb; 51(2):247-53. PubMed ID: 21985132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eligibility, compliance and persistence of sequential therapy with aromatase inhibitors following 2-3 years of tamoxifen in endocrine adjuvant breast cancer therapy.
    Kilic N; Myrick ME; Schmid SM; Gueth U
    Oncology; 2011; 81(3-4):151-7. PubMed ID: 22041855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High non-compliance in the use of letrozole after 2.5 years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial.
    Fontein DB; Nortier JW; Liefers GJ; Putter H; Meershoek-Klein Kranenbarg E; van den Bosch J; Maartense E; Rutgers EJ; van de Velde CJ
    Eur J Surg Oncol; 2012 Feb; 38(2):110-7. PubMed ID: 22172646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compliance and persistence of endocrine adjuvant breast cancer therapy.
    Güth U; Myrick ME; Kilic N; Eppenberger-Castori S; Schmid SM
    Breast Cancer Res Treat; 2012 Jan; 131(2):491-9. PubMed ID: 21976056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of adjuvant endocrine breast cancer therapy in the oldest old.
    Güth U; Myrick ME; Kandler C; Vetter M
    Breast; 2013 Oct; 22(5):863-8. PubMed ID: 23541734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond tamoxifen: extended and late extended endocrine therapy in postmenopausal early breast cancer.
    Dodwell D; Williamson D
    Cancer Treat Rev; 2008 Apr; 34(2):137-44. PubMed ID: 18006236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current controversies in extended adjuvant endocrine therapy for early breast cancer.
    Snoj N; Paridaens R; Cufer T
    Curr Opin Oncol; 2008 Nov; 20(6):627-33. PubMed ID: 18841043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duration of adjuvant endocrine therapy of breast cancer: how much is enough?
    Ward JH
    Curr Opin Obstet Gynecol; 2010 Feb; 22(1):51-5. PubMed ID: 19952743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy.
    Hadji P
    Crit Rev Oncol Hematol; 2010 Feb; 73(2):156-66. PubMed ID: 19299162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Current adjuvant endocrine treatment of breast cancer].
    Dedes KJ; Gabriel N; Fink D
    Gynakol Geburtshilfliche Rundsch; 2008; 48(3):130-7. PubMed ID: 18566529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
    Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
    Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug switch because of treatment-related adverse side effects in endocrine adjuvant breast cancer therapy: how often and how often does it work?
    Güth U; Myrick ME; Schötzau A; Kilic N; Schmid SM
    Breast Cancer Res Treat; 2011 Oct; 129(3):799-807. PubMed ID: 21750963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Towards optimal endocrine therapy for hormone-sensitive breast cancer: initial versus sequential adjuvant aromatase inhibition.
    Spicer J; Ellis P
    Cancer Lett; 2007 Apr; 248(2):165-74. PubMed ID: 16919870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence to adjuvant endocrine therapy in women with breast cancer.
    Danilak M; Chambers CR
    J Oncol Pharm Pract; 2013 Jun; 19(2):105-10. PubMed ID: 22895656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?
    Kaufmann M; Rody A
    Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):146-54. PubMed ID: 16621229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy.
    Filipits M; Rudas M; Heinzl H; Jakesz R; Kubista E; Lax S; Schippinger W; Dietze O; Greil R; Stiglbauer W; Kwasny W; Nader A; Stierer M; Gnant MF;
    Clin Cancer Res; 2009 Sep; 15(18):5888-94. PubMed ID: 19723645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
    Goss PE
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S8-12. PubMed ID: 16730271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
    Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
    Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer.
    Buzdar A; Chlebowski R; Cuzick J; Duffy S; Forbes J; Jonat W; Ravdin P
    Curr Med Res Opin; 2006 Aug; 22(8):1575-85. PubMed ID: 16870082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
    Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
    Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.